摘要
异基因造血干细胞移植是目前治疗白血病、淋巴瘤等恶性血液疾病的有效手段,但是其疗效却受到了移植后发生的移植物抗宿主病的制约与限制。近年来,随着对CD4^+CD25^+调节性T细胞(Treg)研究的深入,人们发现这一T细胞亚群不仅在维持免疫自稳和抑制异体免疫应答方面具有重要作用,并且对于预防与治疗移植物抗宿主病也有一定的潜力。
However allo-hematopoietie stem cell transplantation is the crucial treatment of hematologic malignant diseases sueh as Leukemia and lymphoma, the curative effeet of HSCT is hampered by the ineidenee of GVHD after transplantation. In recent years, with the development of CD4^+ CD25^+ regulatory T cells study, researchers have realized this T cell subset not only play an essential role in maintenance of immune homeostasis and inhibition of allograft immune response, but for the prevention and treatment of GVHD also has certain po- tential. This article foeuses on the biological features of regulatory T eells and the research development of it for prevention and treatment of GVI-ID.
出处
《国际免疫学杂志》
CAS
2012年第6期461-465,共5页
International Journal of Immunology
关键词
调节性T细胞
移植物抗宿主病
造血干细胞移植
Regulatory T cells
Graft-versus-host disease
Hematopoietie stem cell transplantation